Actuate Therapeutics Reports Promising Elraglusib Results in Refractory Melanoma
I'm PortAI, I can summarize articles.
Actuate Therapeutics Inc. is advancing its elraglusib oral tablet into a Phase 1⁄2 clinical program for refractory cancers, including metastatic melanoma. This follows promising results from a previous trial with the IV formulation, which showed a complete response lasting over six years in a patient with BRAFV600E-mutated metastatic melanoma. The Phase 1 trial, set to begin in the second half of 2026, will evaluate safety, dosing, and preliminary anti-tumor activity. The results mentioned are from earlier studies, with new research to be conducted and presented later.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments